Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $4.8 million.

  • Aligos Therapeutics' Other Accumulated Expenses rose 7564.62% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 7564.62%. This contributed to the annual value of $5.0 million for FY2024, which is 2418.21% down from last year.
  • As of Q3 2025, Aligos Therapeutics' Other Accumulated Expenses stood at $4.8 million, which was up 7564.62% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Other Accumulated Expenses registered a high of $6.6 million during Q4 2023, and its lowest value of $483000.0 during Q2 2021.
  • Over the past 5 years, Aligos Therapeutics' median Other Accumulated Expenses value was $1.5 million (recorded in 2022), while the average stood at $2.4 million.
  • In the last 5 years, Aligos Therapeutics' Other Accumulated Expenses skyrocketed by 35030.55% in 2023 and then tumbled by 2418.21% in 2024.
  • Aligos Therapeutics' Other Accumulated Expenses (Quarter) stood at $1.2 million in 2021, then rose by 19.27% to $1.5 million in 2022, then surged by 350.31% to $6.6 million in 2023, then dropped by 24.18% to $5.0 million in 2024, then dropped by 4.06% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $3.8 million for Q2 2025, and $3.9 million during Q1 2025.